Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Anti-CLL1/CD33 CAR-T in Refractory/Recurrent AML
NCT05943314Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of Anti-CLL1/CD33 CAR-T in acute myeloid leukemia (AML), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Changes in cytokine level after CLL1/+CD33 CAR-T infusion at 12 months, Change characteristics of chimeric antigen receptor(CAR)-T cell number at 12 months and 1 more. Planned start Jul 2023; status: withdrawn.
02
Drugs
Anti-CLL1/CD33 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05943314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943314.